Page last updated: 2024-11-11

k11002

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9829299
CHEMBL ID327624
SCHEMBL ID7349448
MeSH IDM0527279

Synonyms (9)

Synonym
CHEMBL327624 ,
SCHEMBL7349448
bdbm50503647
n-[(2s)-1-[[(e,3s)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]morpholine-4-carboxamide
K11002 ,
n-((s)-1-oxo-3-phenyl-1-(((s,e)-5-phenyl-1-(phenylsulfonyl)pent-1-en-3-yl)amino)propan-2-yl)morpholine-4-carboxamide
1348565-08-1
GLXC-25948
PD128854
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Procathepsin LHomo sapiens (human)Ki1.00000.00001.10139.3000AID1514538
Cathepsin BHomo sapiens (human)Ki11.00000.00001.21808.6000AID1514536
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
proteolysisCathepsin BHomo sapiens (human)
thyroid hormone generationCathepsin BHomo sapiens (human)
collagen catabolic processCathepsin BHomo sapiens (human)
epithelial cell differentiationCathepsin BHomo sapiens (human)
regulation of apoptotic processCathepsin BHomo sapiens (human)
decidualizationCathepsin BHomo sapiens (human)
symbiont entry into host cellCathepsin BHomo sapiens (human)
proteolysis involved in protein catabolic processCathepsin BHomo sapiens (human)
cellular response to thyroid hormone stimulusCathepsin BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityCathepsin BHomo sapiens (human)
protein bindingCathepsin BHomo sapiens (human)
collagen bindingCathepsin BHomo sapiens (human)
peptidase activityCathepsin BHomo sapiens (human)
cysteine-type peptidase activityCathepsin BHomo sapiens (human)
proteoglycan bindingCathepsin BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular regionCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
external side of plasma membraneCathepsin BHomo sapiens (human)
apical plasma membraneCathepsin BHomo sapiens (human)
endolysosome lumenCathepsin BHomo sapiens (human)
melanosomeCathepsin BHomo sapiens (human)
perinuclear region of cytoplasmCathepsin BHomo sapiens (human)
collagen-containing extracellular matrixCathepsin BHomo sapiens (human)
extracellular exosomeCathepsin BHomo sapiens (human)
peptidase inhibitor complexCathepsin BHomo sapiens (human)
ficolin-1-rich granule lumenCathepsin BHomo sapiens (human)
extracellular spaceCathepsin BHomo sapiens (human)
lysosomeCathepsin BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID1514536Inhibition of cathepsin B (unknown origin) using Z-Arg-Arg-AMC as substrate after 5 mins by fluorimetric method2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.
AID679233TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCK cells1998Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 26, Issue:4
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
AID757408Inhibition of Trypanosoma brucei recombinant rhodesain2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.
AID213974Effect on survival time of against J744 macrophages infected with Trypanosoma cruzi trypomastigotes at a concentration of 10 uM2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain.
AID757412Antitrypanosomal activity against blood stream form of Trypanosoma brucei brucei2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.
AID54700Second order rate constant for inactivation of cruzain of Trypanosoma cruzi2001Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20
Potent second generation vinyl sulfonamide inhibitors of the trypanosomal cysteine protease cruzain.
AID1514539Inhibition of cathepsin L (unknown origin) assessed as ratio of Kinact to Ki using Z-Phe-Arg-AMC as substrate after 5 mins by fluorimetric method2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.
AID1514538Inhibition of cathepsin L (unknown origin) using Z-Phe-Arg-AMC as substrate after 5 mins by fluorimetric method2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.
AID679890TP_TRANSPORTER: inhibition of photolabeling by Azidopine (Azidopine: 0.05 uM, K02: 10 uM) in membranes from CEM5k cells1998Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 26, Issue:4
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
AID757409Oral bioavailability in Sprague-Dawley rat2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.
AID757407Antitrypanosomal activity against procyclic form of Trypanosoma brucei brucei2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.
AID1514537Inhibition of cathepsin B (unknown origin) assessed as ratio of Kinact to Ki using Z-Arg-Arg-AMC as substrate after 5 mins by fluorimetric method2019Bioorganic & medicinal chemistry letters, 01-01, Volume: 29, Issue:1
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments.
AID679289TP_TRANSPORTER: inhibition of photolabeling by LU-49888 (LU-49888: 0.1 uM, K02: 10 uM) in membranes from CEM5k cells1998Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 26, Issue:4
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.06 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]